Aberrant activation of the epidermal growth factor receptor (EGFR/ERBB1) by erythroblastic
leukemia viral oncogene homolog (ERBB) ligands contributes to various tumor …

KRAS mutations are one of the most common driver mutations in non-small-cell lung cancer
(NSCLC) and finding druggable target molecules to inhibit oncogenic KRAS signaling is a …

Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …

Introduction: Cancer is a devastating disease; however, several therapeutic advances have
recently been made, wherein EGFR and its family members have emerged as useful …

Background Epidermal growth factor (EGF) receptors contribute to the development of
malignant glioma. Here we considered the possible implication of the EGFR ligand …

Members of the epidermal growth factor receptor (EGFR/ErbB) family play a critical role in
normal cell growth and development. However, many ErbB family members, especially …

The epidermal growth factor receptor (EGFR) is a member of the EGFR family of receptor
tyrosine kinases (RTKs). EGFR activation via ligand binding results in signaling through …

Despite a well-established role for the epidermal growth factor receptor (EGFR) in
tumorigenesis, EGFR activities and endocytosis in tumors in vivo have not been studied. We …

• Introduction• Endocytosis of EGFR‐Kinase activity‐Clathrin‐coated pits‐Ubiquitination‐
Effects of EGFR‐ErbB2 heterodimerization on EGFR internalization• Cellular and molecular …

The discovery that signaling by the epidermal growth factor receptor (EGFR) plays a key role
in tumorigenesis prompted efforts to target this receptor in anticancer therapy. Two different …